Library Item - Page 44 of 792 Posts on Medivizor
Navigation Menu

Library Item Posts on Medivizor

Comparing the effectiveness and safety of single and double immune checkpoint inhibitor-based first-line treatments for advanced non-small cell lung cancer.

Comparing the effectiveness and safety of single and double immune checkpoint inhibitor-based first-line treatments for advanced non-small cell lung cancer.

Posted by on Oct 16, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of single and double immune checkpoint inhibitors (ICI)-based treatments in patients with advanced non-small-cell lung cancer (NSCLC). The data showed that the effectiveness and safety of both single and double ICI-based treatments were similar and higher...

Read More

Evaluating the effectiveness and safety of different anti-HER2 therapies in combination with chemotherapy for metastatic HER2-positive breast cancer.

Evaluating the effectiveness and safety of different anti-HER2 therapies in combination with chemotherapy for metastatic HER2-positive breast cancer.

Posted by on Oct 16, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of different anti-HER2 therapies in combination with chemotherapy for the treatment of patients with metastatic HER2-positive breast cancer (BC). The data showed that THP (taxanes + trastuzumab + pertuzumab) was the best first-line treatment, while Trastuzumab emtansine (T-DM1; Kadcycla) and...

Read More

Evaluating minimal residual disease with clinical outcomes in Philadelphia chromosome positive acute lymphoblastic leukemia 

Evaluating minimal residual disease with clinical outcomes in Philadelphia chromosome positive acute lymphoblastic leukemia 

Posted by on Oct 16, 2021 in Leukemia | 0 comments

In a nutshell This review aimed to investigate the prognostic value of minimal residual disease (MRD) in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).  This review concluded that MRD is a good predictor of outcomes in these patients.   Some background Ph+ ALL is an aggressive type of...

Read More

Evaluating the benefits of radiotherapy after surgery in patients with resectable stage III-N2 non-small cell lung cancer.

Evaluating the benefits of radiotherapy after surgery in patients with resectable stage III-N2 non-small cell lung cancer.

Posted by on Oct 16, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the benefits of postoperative radiotherapy (PORT; radiation after surgery) in patients with resectable stage III-N2 non-small-cell lung cancer (NSCLC). The data showed that PORT significantly increased survival without disease progression and reduced the risk of cancer relapse for these patients. Some background...

Read More

Treatment responses to tofacitinib with additional therapies in patients with rheumatoid arthritis.

Treatment responses to tofacitinib with additional therapies in patients with rheumatoid arthritis.

Posted by on Oct 16, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study assessed the responses of patients with rheumatoid arthritis (RA) to tofacitinib (Xeljanz), tofacitinib with methotrexate (MTX; Otrexup), and adalimumab (Humira) with MTX. The data showed that some patients did not require combined therapy to achieve higher responses, however, overall, greater responses were achieved with...

Read More

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Posted by on Oct 9, 2021 in Lung cancer | 0 comments

In a nutshell This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT).   Some background Immunotherapy is a type of cancer treatment that makes use of the immune...

Read More

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Posted by on Oct 9, 2021 in Melanoma | 0 comments

In a nutshell This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT).   Some background Immunotherapy is a type of cancer treatment that makes use of the...

Read More

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Posted by on Oct 9, 2021 in Colorectal cancer | 0 comments

In a nutshell This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT).   Some background Immunotherapy is a type of cancer treatment that makes use of the immune...

Read More